4.04 USD
-0.08 (-1.95%)
We assign a fundamental rating of 3 out of 10 to MOLN. MOLN was compared to 533 industry peers in the Biotechnology industry. The financial health of MOLN is average, but there are quite some concerns on its profitability. MOLN does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
MOLN had negative earnings in the past year.
MOLN had a negative operating cash flow in the past year.
In the past 5 years MOLN reported 4 times negative net income.
MOLN had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -48.19%, MOLN is in line with its industry, outperforming 51.59% of the companies in the same industry.
With a decent Return On Equity value of -56.57%, MOLN is doing good in the industry, outperforming 63.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.19% | ||
| ROE | -56.57% | ||
| ROIC | N/A |
ROA(3y)-6.8%
ROA(5y)-18.16%
ROE(3y)-7.72%
ROE(5y)-28.23%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 99.80%, MOLN belongs to the top of the industry, outperforming 98.50% of the companies in the same industry.
MOLN's Gross Margin has been stable in the last couple of years.
MOLN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.8% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.14%
GM growth 5Y0.01%
2. Health
2.1 Basic Checks
MOLN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MOLN has more shares outstanding
Compared to 5 years ago, MOLN has more shares outstanding
Compared to 1 year ago, MOLN has an improved debt to assets ratio.
2.2 Solvency
MOLN has an Altman-Z score of 0.08. This is a bad value and indicates that MOLN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.08, MOLN is in the better half of the industry, outperforming 62.85% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that MOLN is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.00, MOLN perfoms like the industry average, outperforming 47.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.08 |
ROIC/WACCN/A
WACC4.88%
2.3 Liquidity
A Current Ratio of 9.28 indicates that MOLN has no problem at all paying its short term obligations.
MOLN has a better Current ratio (9.28) than 80.11% of its industry peers.
MOLN has a Quick Ratio of 9.28. This indicates that MOLN is financially healthy and has no problem in meeting its short term obligations.
MOLN's Quick ratio of 9.28 is amongst the best of the industry. MOLN outperforms 80.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.28 | ||
| Quick Ratio | 9.28 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 16.05% over the past year.
MOLN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -29.38%.
MOLN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -24.59% yearly.
EPS 1Y (TTM)16.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.65%
Revenue 1Y (TTM)-29.38%
Revenue growth 3Y-20.13%
Revenue growth 5Y-24.59%
Sales Q2Q%-100%
3.2 Future
Based on estimates for the next years, MOLN will show a decrease in Earnings Per Share. The EPS will decrease by -4.17% on average per year.
Based on estimates for the next years, MOLN will show a very strong growth in Revenue. The Revenue will grow by 97.66% on average per year.
EPS Next Y9.15%
EPS Next 2Y11.39%
EPS Next 3Y17.71%
EPS Next 5Y-4.17%
Revenue Next Year-75%
Revenue Next 2Y65.83%
Revenue Next 3Y128.15%
Revenue Next 5Y97.66%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
MOLN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MOLN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MOLN's earnings are expected to grow with 17.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.39%
EPS Next 3Y17.71%
5. Dividend
5.1 Amount
MOLN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:MOLN (11/21/2025, 8:00:01 PM)
4.04
-0.08 (-1.95%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners45.05%
Inst Owner Change-0.13%
Ins Owners4%
Ins Owner ChangeN/A
Market Cap151.09M
Revenue(TTM)4.97M
Net Income(TTM)-54.04M
Analysts82.22
Price Target15.45 (282.43%)
Short Float %0.08%
Short Ratio4.13
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.84%
PT rev (3m)17.61%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)4.85%
EPS NY rev (3m)6.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 24.54 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.28 | ||
| P/tB | 1.28 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.89
EYN/A
EPS(NY)-1.51
Fwd EYN/A
FCF(TTM)-1.79
FCFYN/A
OCF(TTM)-1.77
OCFYN/A
SpS0.16
BVpS3.16
TBVpS3.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.19% | ||
| ROE | -56.57% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 99.8% | ||
| FCFM | N/A |
ROA(3y)-6.8%
ROA(5y)-18.16%
ROE(3y)-7.72%
ROE(5y)-28.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.14%
GM growth 5Y0.01%
F-Score3
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 32.33% | ||
| Cap/Sales | 14.33% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.28 | ||
| Quick Ratio | 9.28 | ||
| Altman-Z | 0.08 |
F-Score3
WACC4.88%
ROIC/WACCN/A
Cap/Depr(3y)41.08%
Cap/Depr(5y)46.5%
Cap/Sales(3y)8.93%
Cap/Sales(5y)11.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.65%
EPS Next Y9.15%
EPS Next 2Y11.39%
EPS Next 3Y17.71%
EPS Next 5Y-4.17%
Revenue 1Y (TTM)-29.38%
Revenue growth 3Y-20.13%
Revenue growth 5Y-24.59%
Sales Q2Q%-100%
Revenue Next Year-75%
Revenue Next 2Y65.83%
Revenue Next 3Y128.15%
Revenue Next 5Y97.66%
EBIT growth 1Y-0.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.11%
EBIT Next 3Y39.98%
EBIT Next 5YN/A
FCF growth 1Y7.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.95%
OCF growth 3YN/A
OCF growth 5YN/A
MOLECULAR PARTNERS AG -ADR / MOLN FAQ
What is the ChartMill fundamental rating of MOLECULAR PARTNERS AG -ADR (MOLN) stock?
ChartMill assigns a fundamental rating of 3 / 10 to MOLN.
What is the valuation status of MOLECULAR PARTNERS AG -ADR (MOLN) stock?
ChartMill assigns a valuation rating of 0 / 10 to MOLECULAR PARTNERS AG -ADR (MOLN). This can be considered as Overvalued.
Can you provide the profitability details for MOLECULAR PARTNERS AG -ADR?
MOLECULAR PARTNERS AG -ADR (MOLN) has a profitability rating of 2 / 10.
Can you provide the financial health for MOLN stock?
The financial health rating of MOLECULAR PARTNERS AG -ADR (MOLN) is 5 / 10.
What is the earnings growth outlook for MOLECULAR PARTNERS AG -ADR?
The Earnings per Share (EPS) of MOLECULAR PARTNERS AG -ADR (MOLN) is expected to grow by 9.15% in the next year.